公开(公告)号：US20220347194A1

公开(公告)日：2022-11-03

申请号：US17761014

申请日：2020-09-18

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： MAHMOUD SALMA AHMED ,  ENAS KANDIL ,  HESHAM SADEK ,  PING WANG ,  ROBERT BACHOO ,  MARK HENKEMEYER

IPC: A61K31/65 ,  A61K31/167 ,  A61K31/165 ,  A61K31/045 ,  A61K31/195 ,  A61P29/00 ,  A61P35/00 ,  A61K45/06

Abstract: Inhibition of EphB receptors (e.g., EphB1) can be used in therapeutic methods for treating EphB receptor-associated conditions (e.g., pain, cancer). Demeclocycline, chlortetracycline, and minocycline are identified as EphB receptor inhibitors. Accordingly, aspects of the disclosure relate to methods for treating pain comprising providing demeclocycline, chlortetracycline, minocycline, or derivatives thereof, alone or in combination, to an individual in need thereof. Further aspects relate to pharmaceutical compositions comprising two or more of minocycline, demeclocycline, chlortetracycline, and/or derivatives thereof.